Management of newly diagnosed hepatitis C virus infection

All patients with chronic hepatitis C virus infection are potential candidates for antiviral therapy. Careful patient selection can optimize the response to therapy and enhance safety. Pegylated forms of interferon, when combined with ribavirin, can "cure" the majority of patients undergoi...

Full description

Saved in:

Bibliographic Details
Published in:	Cleveland Clinic journal of medicine Vol. 70; no. Suppl 4; p. S14
Main Authors:	Russo, Mark W, Zacks, Steven L, Fried, Michael W
Format:	Journal Article
Language:	English
Published:	United States Cleveland Clinic 01-09-2003
Subjects:	Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Clinical Trials as Topic Contraindications Drug Therapy, Combination Hepatitis C, Chronic - drug therapy Humans Interferon alpha-2 Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Patient Compliance Patient Selection Prognosis Recombinant Proteins Ribavirin - adverse effects Ribavirin - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	All patients with chronic hepatitis C virus infection are potential candidates for antiviral therapy. Careful patient selection can optimize the response to therapy and enhance safety. Pegylated forms of interferon, when combined with ribavirin, can "cure" the majority of patients undergoing therapy, and these agents have become the new standard of care for chronic hepatitis C. Careful and timely management of side effects, which are experienced by all patients, can improve adherence to antiviral therapy and further improve response rates.
ISSN:	0891-1150 1939-2869
DOI:	10.3949/ccjm.70.Suppl_4.S14